Brief: Krystal Biotech Announces Positive Interim Clinical Update From KB407 Phase 1 CORAL-1 Study
08/01/2026 21:10
Jan 8 (Reuters) - Krystal Biotech Inc KRYS.O: KRYSTAL BIOTECH ANNOUNCES POSITIVE INTERIM CLINICAL UPDATE FROM KB407 PHASE 1 CORAL-1 STUDY WITH CONFIRMATION OF WILD-TYPE CFTR DELIVERY TO THE LUNGS OF PATIENTS WITH CYSTIC FIBROSIS KRYSTAL BIOTECH INC - SERIOUS ADVERSE EVENT OF ASTHMA EXACERBATION REPORTED 24 HOURS AFTER COMPLETION OF THE BRONCHOSCOPY Source text: ID:nGNX5mnY17 Further company coverage: KRYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion